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Design, synthesis and pharmacological screening of b-amino-, 
thiadiazole/thiadiazine-phosphonate based triazole motifs as 
antimicrobial/cytotoxic agents
Three different series of phosphonate derivatives, b-amino- 
and fused thiadiazolo/thiadiazine-phosphonates have 
been synthesized using the addition and/or addition-cycli-
zation protocol of Horner-Wadsworth-Emmons (HWE) re-
agents to 1,2,4-triazole-3-thiols. The design of potentially 
antimicrobial and anticancer phosphor esters relied on the 
results of computer-assisted molecular modeling. All syn-
thesized phosphonates were evaluated for their in vitro an-
timicrobial activities while anticancer properties were de-
termined for eight out of twenty new phosphonates. The 
tested phosphonates, except for compounds that have a ni-
trile moiety, exhibited moderate to significant antimicro-
bial activity. Nevertheless, the most active compounds 
were fused thiadiazole-phosphonates, which inhibited the 
growth of both Gram-negative and Gram-positive bacteria 
better than b-aminophosphonates and fused thiadiazolophos-
phonates. In parallel, the antitumor activity screenings of 
selected phosphonates from each series and substra te 1 
were also done. Their antitumor properties against ten car-
cinoma cell lines, including breast (MCF7, MDA-MB- 231/
ATCC, MDA-MB-435, BT-549), ovarian (IGROVI, OVCAR-3, 
SK-OV-3), prostate (PX-3, PU-145), and liver (HEPG2), were 
investigated. The results showed that all synthesized com-
pounds reflected remarkable antitumor activity against 
breast (especially MDA-MB-231/ATCC and BT-549), and 
pro state carcinoma cell lines (PC-3 and DU-145), whereas a 




agents, in vitro antimicrobial/antineoplastic activity
The alarming rates of growing antibiotic resistance are major threats to public health 
and scientific communities worldwide, especially in the field of multidrug-resistant bacte-
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ria and fungi (1). In addition, cancer is among the most critical health issues and is consid-
ered to be the second leading cause of death, just after circulatory diseases. Despite the 
availability of improved drugs, including targeted cancer therapies, according to the 
World Health Organization (WHO), the worldwide cancer burden is expected to increase 
by as much as 50 % by the year 2020 unless further preventive measures are put into prac-
tice (2). These trends have emphasized the urgent need for new, more effective and safe 
antimicrobial and/or antitumor drugs that may have dual/multiple action towards bio-
logical targets (3, 4).
Chemistry of N-bridged heterocyclic compounds, such as triazoles, especially 1,2,4-tri-
azoles, has received considerable attention in recent years due to their biological ac tivities. 
However, a number of biological activities such as antiinflammatory, analgesic and others 
are associated with the N-substituted 1,2,4-triazole nucleus attached with different hetero-
cycles (5, 6). Furthermore, over the last two decades, a continuous trend is observed toward 
the chemistry of N,P-heterocycles and derived phosphonates, largely, because these com-
pounds tend to have high antibiotic (7) and antitumor potencies (8). Moreover, the 1,2,4-tri-
azole nucleus has been incorporated into a wide variety of therapeutically important 
agents. Ribavirin, posaconazole, fluconazole and itraconazole are efficient antibacterial 
and/or antifungal drugs used in current treatments (9). Further, vorozole, letrozole and 
anastrozole are some examples of antitumor drugs containing the 1,2,4-triazole moiety 
(10). In view of these observations and our program of synthesis of 5-membered N-hetero-
cycle phosphor esters with antibiotic (11-13) and anticancer properties (14-16), we report 
herein the synthesis of three series of b-amino-, fused thiadiazolo-, and thiadiazino-phos-
phonate-based 1,2,4-triazole motifs. Optimized antimicrobial and cytotoxic activity of 
newly-synthesized phosphonates was based on potency prediction using the computer-
assisted molecular modeling (CAMM) (17, 18).
EXPERIMENTAL
General
Melting points were determined with an open capillary tube on an Electrothermal 
(variable heater, Stuart, UK) melting point apparatus and were corrected. IR spectra were 
recorded on a JASCO FT-IR 6100 using a KBr disc (JASCO, Japan). NMR spectra were mea-
sured with a JEOL E.C.A-500 MHz (13C: 125.4 MHz, 1H: 500.7 MHz, 31P: 200.7 MHz) spec-
trometer (JEOL, Japan). 31P NMR spectra were recorded with H3PO4 (85 %) as external 
reference, 1H and 13C NMR spectra were recorded with trimethylsilane as internal stan-
dard in CDCl3. Chemical shifts (d) are given in ppm. Mass spectra were recorded at 70 eV 
on an MS-50 Kratos (A.E.I.) spectrometer (Kratos, UK). Elemental analyses were carried 
out at the Microanalysis Laboratory, Cairo University. Elemental analyses were performed 
using elementary Analysensysteme GmbH-vario EL III Element Analyzer (Germany). 
Compounds 4-(4-(dimethylamino)benzylideneamino)-4H-1,2,4-triazole-3-thiol (1) and 
4-(4-chlorobenzylidene-amino)-4H-1,2,4-triazole-3-thiol (2) were obtained using the pro-
cedures reported elsewhere (19, 20). Phosphonyl carbanion reagents: [diethyl (2-amino-2-
thioxoethyl)-, diethyl cyanomethylphosphonate, methyl diethyl-, triethyl phosphonoace-
tate, diethyl (methylthiomethyl)phosphonates, diethyl (methylthioethyl)phosphonate and 
diethyl 2-methylallylphosphonate] were purchased from Sigma-Aldrich Company (USA).
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General synthesis procedure
Synthesis of 3a-h and 4a-h. – A solution of LiH (0.1 g, 12.6 mmol) in DMF (20 mL) and 
the phosphonyl carbanion (4.2 mmol) [diethyl (2-amino-2-thioxoethyl)-, diethyl cyano-
methylphosphonate, methyl diethyl- or triethyl phosphonoacetate] was stirred at 0 °C for 
about 0.5 h. A solution of 1 (0.86 g, 3.5 mmol) or 2 (0.83 g, 3.5 mmol) in 10 mL of DMF was 
then added in one portion. After the evolution of H2 had ceased, the suspension was stirred 
at room temperature for further 30 min and then heated under reflux for appropriate time 
(≈6 h, TLC). After completion of the reaction, the produced mixture was cooled, poured 
into ice-water, and acidified with HCl (1 mol L–1) to pH ≈5, followed by extraction with 
ethyl acetate (3×50 mL). The combined organic phase was dried over anhydrous Na2SO4. 
After removal of the volatile material under vacuum, the resulting residue was chromato-
graphed on silica gel with n-hexane/CHCl3 (7:3, V/V) to give the corresponding products 
4a-h, followed by elution with n-hexane/CHCl3 (1:1, V/V) to give 3a-h.
When the above reactions (1/2 with the same phosphorus reagents) proceeded in 
MeOH solution containing sodium methanoate (MeONa) and a catalytic amount of 2,3-di-
chloro-5,6-dicyanobenzoquinone (DDQ), thiadiazolo-phosphonates 4a-h were exclusively 
obtained in 75–80 % yield.
Reaction of 1/2 with diethyl (methylthiomethyl)phosphonate and diethyl (methylthioethyl)
phosphonate
Synthesis of 6a and b. – According to the general procedure, a mixture of 1 (0.86 g, 3.5 
mmol), diethyl (methylthiomethyl)phosphonate (0.83 g, 4.2 mmol) or diethyl (methylthio-
ethyl)phosphonate (0.89 g, 4.2 mmol), 0.1 g of sodium (8.4 mmol), and a catalytic amount of 
DDQ in 20 mL MeOH was stirred at room temperature for half an hour. The reaction mix-
ture was further refluxed for ≈6 h (TLC) to give a material that was assigned thiadiazine-
2-phosphonate (6a).
The same procedure and addition of the same amounts to the reaction of 2 with di-
ethyl (methylthiomethyl)phosphonate (0.83 g, 4.2 mmol) or diethyl (methylthio-ethyl)phos-
phonate afforded the corresponding thiadiazine-2-phosphonate 6b.
Reaction of 1/2 with diethyl 2-methylallylphosphonate
Synthesis of 8a,b. – Following the general procedure and using the same amounts, 1/2 re-
acted with diethyl 2-methylallylphosphonate (0.80 g, 4.2 mmol) in the presence of DDQ to 
give phosphonates 8a or 8b after heating under reflux for 8 h.
Solvents of crystallization, yields, physical analytical data and spectral data (MS, IR, 
1H-, 13C-, and 31P-NMR) for the new products 3a-h, 4a-h, 6a,b and 8a,b are collected in Ta-
bles I and II.
Pharmacology
Biological activity spectra prediction. – Biological activity spectra were predicted for sub-
strates 1/2 and synthesized structures 3a-h, 4a-h, 6a,b, 8a and b with the molecular as-
sisted program PASS 2009.1 version (IBMC, Moscow, Russia). The prediction result is pre-
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Table I. Physical and analytical data for compounds 3a-h, 4a-h, 6a, b, 8a and b
Product / appearance M.p.  (oC)/yield (%) 
Mol. form. (Mr)
MS: m/z (%) = [M+]
Calcd./found (%)
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Solvents for crystalization: a EtOH, b cyclohexane, c MeCN, d acetone, e CH2Cl2/Me2O (1:1, V/V), f ligroin, g pentane, 
h acetone, i CHCl3, j EtOH/Me2O (1:1, V/V). 
Table II. IR, 1H-, 31P- and 13C NMR spectral data for compounds 3a-h, 4a-h, 6a, b, 8a and b
Compd. IR  
(KBr, nmax, cm–1)
1H and 31P NMR (d, ppm) 13C NMR (d, ppm)
3a 3408, 3318 (NH, 




1.18 (dt, 3JH-H = 6.7, 4JP-H  = 4.4 Hz, 6H, 
2MeCOP), 2.82 (br, 1H, HS), 2.94 
(s, 6H, NMe2), 3.24 (dd, 3JH-H = 15.7, 
2JP-H  = 20.6 Hz, 1H, HaC-P), 4.34 (dq, 
3JH-H = 6.7, 3JP-H = 7.1 Hz, 4H, 2H2CO), 
4.58 (m, 1H, HbC), 6.68, 7.68 (2d, 
3JH-H = 9.4 Hz, 4H, H-Ar), 8.58 (s, 1H, 
HC-triazole), 10.33 (d, 
3JH-H = 6.8 Hz, 
1H, HN), 11.2 (br, 2H, H2N); dP 21.4
205.6 (d, 2JP-C = 10.4 Hz, CSNH2), 
156.6 (C(5)-triazole), 140.3 (C(3)-tri-
azole), 149.5, 137.5, 129.2, 112.3 
(C-Ar), 63.5 (d, 2JP-C = 10.2 Hz, CHb), 
61.1 (d, 2JP-C = 8.7 Hz, H2COP), 58.5 
(d, 1JP-C = 165.4 Hz, C-P), 39.5 
(Me2N), 16.2 (d, 3JP-C = 7.5 Hz, 
MeCOP)
3b 3348 (NH), 2410 




1.34 (dt, 3JH-H = 6.5, 4JP-H = 4.9 Hz, 6H, 
2MeCOP), 2.64 (br, 1H, HS), 2.99 
(s, 6H, NMe2), 3.26 (dd, 3JH-H = 17.4, 
2JP-H = 20.1 Hz, 1H, HaC-P), 4.22 (dq, 
3JH-H = 6.5, 3JP-H = 6.8 Hz, 4H, 2H2COP), 
4.81 (m, 1H, HbC), 6.64, 7.64 (2d, 
3JH-H = 9.2 Hz, 4H, H-Ar), 8.27 (s, 1H, 
HC-triazole), 10.12 (d, 
3JH-H = 6.7 Hz, 
1H, HN); dP 24.2
157.1 (C(5)-triazole), 140.8 (C(3)-tri-
azole), 150.1, 134.5, 133.1, 112.6 
(C-Ar), 111.3 (d, 2JP-C = 8.5 Hz, CN), 
62.5 (d, 2JP-C = 8.5 Hz, H2COP), 60.5 
(d, 2JP-C = 11.3 Hz, CHb), 40.2 (NMe2), 
35.8 (d, 1JP-C = 183.6 Hz, C-P), 16.5 
(d, 3JP-C = 7.3 Hz, MeCOP)
3c 3422 (NH), 2385 




1.27 (dt, 3JH-H = 6.9, 4JP-H  = 4.8 Hz, 
6H, 2H3CCOP), 2.38 (br, 1H, HS), 3.07 
(s, 6H, NMe2), 3.25 (dd, 3JH-H = 13.9, 
2JP-H = 19.8 Hz, 1H, HaC-P), 3.71 (s, 3H, 
MeCO2), 4.15 (dq, 3JH-H = 6.9, 3JP-H = 7.3 
Hz, 4H, 2H2COP), 5.16 (m, 1H, CHb), 
6.62, 7.45 (2d, 3JH-H = 8.7 Hz, 4H, 
H-Ar), 8.07 (s, 1H, HC-triazole), 9.74 
(d, 3JH-H = 6.9 Hz, 1H, HN); dP 22.8
166.1 (d, 2JP-C = 8.9 Hz, C=O), 157.7 
(C(5)-triazole), 141.1 (C(3)-triazole), 
147.5, 135.9, 134.7, 112.1 (C-Ar), 62.4 
(d, 2JP-C = 9.1 Hz, H2COP), 61.7 (d, 
2JP-C = 10.2 Hz, CHb), 52.8 (MeCO2), 
48.6 (d, 1JP-C = 180.6 Hz, C-P), 40.5 
(NMe2), 16.7 (d, 3JP-C = 6.9 Hz, 
H3CCOP)
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3d 3434 (NH), 2419 




1.18-1.32 (m, 9H, MeC.CO2 & 2MeCOP), 
2.40 (br, 1H, HS), 3.13 (s, 6H, NMe2), 
3.32 (dd, 3JH-H = 14.3, 2JP-H = 16.5 Hz, 
1H, HaC-P), 4.16-4.28 (m, 6H, H2CCO2 
& 2H2COP), 5.17 (m, 1H, CHb), 6.68, 
7.67 (2d, 3JH-H = 8.2 Hz, 4H, H-Ar), 8.57 
(s, 1H, HC-triazole), 9.75 (d, 3JH-H = 
6.8 Hz, 1H, HN); dP 21.9
166.3 (d, 2JP-C = 10.2 Hz, C=O), 156.9 
(C(5)-triazole), 141.2 (C(3)-triazole), 
147.3, 135.9, 134.6, 112.6 (C-Ar), 62.9 
(d, 2JP-C = 9.7 Hz, H2CO), 61.8 (d, 
2JP-C= 9.2 Hz, CHb), 60.5 (H2CCO), 
49.2 (d, 1JP-C = 180.6 Hz, C-P), 40.4 
(NMe2), 16.9 (d, 3JP-C = 6.8 Hz, 
MeCOP), 14.5 (MeCCO2)
3e 3395, 3315 (NH, 




1.29 (dt, 3JH-H = 8.3, 4JP-H  = 4.5 Hz, 6H, 
2MeCOP), 2.42 (br, 1H, HS), 3.11 (dd, 
3JH-H = 14.2, 2JP-H = 19.3 Hz, 1H, HaC-P), 
4.15 (dq, 3JH-H = 8.3, 3JP-H = 6.5 Hz, 4H, 
2 H2COP), 4.65 (m, 1H, CHb), 6.99, 7.93 
(2d, 3JH-H = 9.3 Hz, 4H, H-Ar), 8.63 (s, 
HC-triazole), 9.73 (d, 3JH-H = 6.8 Hz, 
1H, HN), 10.85 (br, 2H, H2N); dP 24.7
205.9 (d, 2JP-C = 10.2 Hz, C=S), 157.7 
(C(5)-triazole), 141.3 (C(3)-triazole), 
147.2, 134.6, 133.5, 131.7 (C-Ar), 63.5 
(d, 2JP-C = 10.6 Hz, CHb), 61.9 (d, 
2JP-C = 9.7 Hz, H2COP), 59.5 (d, 1JP-C = 
178.4 Hz, C-P), 16.5 (d, 3JP-C = 7.2 Hz, 
H3CCOP)
3f 3410 (NH), 2428 
(SH), 2219 (CN), 
1229 (P=O), 1082 
(P-O-C)
1.16 (dt, 3JH-H = 6.4, 4JP-H = 4.7 Hz, 6H, 
2MeCOP), 2.54 (br, 1H, HS), 3.31 (dd, 
3JH-H = 10.4, 2JP-H = 23.5 Hz, 1H, HaC-P), 
4.18 (dq, 3JH-H = 6.4, 3JP-H = 7.1 Hz, 4H, 
2H2COP), 5.02 (m, 1H, CHb), 7.45, 7.87 
(2d, 3JH-H = 9.4 Hz, 4H, H-Ar), 8.39 
(s, 1H, HC-triazole), 10.08 (d, 
3JH-H = 
6.8 Hz, 1H, HN); dP 23.6
156.9 (C(5)-triazole), 141.8 (C(3)-tri-
azole), 143.5, 134.7, 133.6, 129.7 
(C-Ar), 111.4 (d, 2JP-C = 11.5 Hz, CN), 
62.3 (d, 2JP-C = 8.7 Hz, H2COP), 
60.7 (d, 2JP-C = 12.1 Hz, CHb), 36.3 (d, 
1JP-C = 183.6 Hz, C-P), 16.4 (d, 3JP-C = 
7.5 Hz, MeCOP)
3g 3372 (NH), 2448 




1.21 (dt, 3JH-H = 6.3, 4JP-H  = 4.5, 6H, 
2MeCOP), 2.66 (br, 1H, HS), 3.66 (dd, 
3JH-H = 13.9, 2JP-H = 19.8 Hz, 1H, HaC-P), 
3.82 (s, 3H, MeC), 4.25 (dq, 3JH-H= 6.3, 
3JP-H= 8.3 Hz, 4H, 2H2CO), 5.23 (m, 
1H, CHb), 7.31, 7.68 (2d, 3JH-H = 8.7 Hz, 
4H, H-Ar), 8.57 (s, 1H, HC-triazole), 
9.64 (d,
 3JH-H = 7.8 Hz, 1H, HN); dP 22.6 
166.5 (d, 2JP-C = 10.3 Hz, CO), 157.5 
(C(5)-triazole), 141.3 (C(3)-triazole), 
144.6, 133.2, 131.7, 129.5 (C-Ar), 
61.9 (d, 2JP-C = 14.6 Hz, CHb), 61.1 (d, 
2JP-C = 9.8 Hz, H2COP), 52.6 (MeCO2), 
47.6 (d, 1JP-C = 169.6 Hz, C-P), 16.5 
(d, 3JP-C = 7.9 Hz, MeCOP)
3h 3431 (NH), 2356 




1.23-1.34 (m, 9H, MeC.CO2 & 
2MeCOP), 2.63 (br, 1H, HS), 3.48 (dd, 
3JH-H = 12.1, 2JP-H = 22.3 Hz, 1H, HaC-P), 
4.15-4.23 (m, 6H, H2CCO2 & 2H2COP), 
5.34 (m, 1H, CHb), 7.24, 7.73 (2d, 3JH-H = 
8.2 Hz, 4H, H-Ar), 8.65 (s, 1H, 
HC-triazole), 10.46 (d, 3JH-H = 6.9 Hz, 
1H, HN); dP 23.1
167.2 (d, 2JP-C = 11.3 Hz, C=O), 156.7, 
141.4 (C(5)-, C(3)-triazole), 144.7, 
135.5, 132.7, 130.6 (C-Ar), 62.8 (d, 
2JP-C = 10.7 Hz, H2COP), 62.4 (d, 
2JP-C = 9.8 Hz, CHb), 61.5 (H2CCO2), 
49.2 (d, 1JP-C = 180.6 Hz, C-P), 16.3 (d, 
3JP-C = 6.2 Hz, MeCOP), 14.2 
 (MeCCO2)
4a 3333-3320 (NH, 
NH2), 1227 (P=O, 
bonded), 1045 
(P-O-C)
1.22 (dt, 3JH-H = 6.7, 4JP-H = 4.3 Hz, 6H, 
2MeC), 2.91 (s, 6H, NMe2), 3.22 (d, 
2JP-H = 18.8 Hz, 1H, HC-P), 4.02 (dq, 
3JH-H = 6.7, 3JP-H = 6.4 Hz, 4H, 2H2COP), 
6.59, 7.65 (2d, 3JH-H = 6.4 Hz, 4H, 
H-Ar), 8.58 (s, 1H, H(3)-triazole), 9.43, 
10.11 (2br, 3H, NH, NH2); dP 26.9
207.6 (d, 2JP-C = 12.5 Hz, C=S), 159.2 
(C(5)-triazole), 141.5 (C(3)-triazole), 
148.5, 137.1, 132.7, 118.5 (C-Ar), 77.5 
(d, 2JP-C = 12.9 Hz, C-NH), 62.7 (d, 
2JP-C = 8.7 Hz, H2COP), 58.7 (d, 1JP-C = 
172.4 Hz, C-P), 39.1 (NMe2), 15.7 (d, 
3JP-C= 6.9 Hz, H3CC-)
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4b 3341 (NH), 2216 
(CN), 1234 (P=O, 
bonded), 1075 
(P-O-C)
1.23 (dt, 3JH-H = 6.1, 4JP-H  = 3.9 Hz, 6H, 
2MeCOP), 2.99 (s, 6H, Me2N), 3.26 (d, 
2JP-H  = 20.5 Hz, 1H, HC-P), 4.22 (dq, 
3JH-H = 6.1, 3JP-H = 5.7 Hz, 4H, 2H2COP), 
6.64, 7.71 (2d, 3JH-H = 9.4 Hz, 4H, 
H-Ar), 8.57 (s, 1H, H(3)-triazole), 9.73 
(br, 1H, HN); dP 27.6
156.3 (C(5)-triazole), 140.2 (C(3), 
triazole), 148.5, 133.5, 131.9, 118.3 
(C-Ar), 117.6 (d, 2JP-C = 9.5 Hz, CN), 
78.3 (d, 2JP-C = 11.9 Hz, C-NH), 61.3 
(d, 2JP-C = 7.9 Hz, H2COP), 41.5 
(N(CH3)2), 58.7 (d, 1JP-C = 184.6 Hz, 
C-P), 15.6 (d, 3JP-C = 6.8 Hz, MeCOP)
4c 3316 (NH), 1701 
(C=O), 1238 (P=O, 
bonded), 1093 
(P-O-C)
1.19 (dt, 3JH-H = 6.6, 4JP-H  = 4.5 Hz, 6H, 
2MeCOP), 2.98 (s, 6H, Me2N), 3.32 (d, 
2JP-H  = 16.8 Hz, 1H, HC-P), 3.76 (s, 3H, 
MeCO2), 4.22 (dq,3JH-H = 6.6, 3JP-H = 
5.8 Hz, 4H, 2 H2COP), 6.65, 7.53 (2d, 
3JH-H = 8.2 Hz, 4H, H-Ar), 8.07 (s, 1H, 
HC-triazole), 9.54 (br, 1H, NH); dP 
24.7
163.1 (d, 2JP-C = 11.8 Hz, C=O), 155.7 
(C(5)-triazole), 141.6 (C(3)-triazole), 
147.3, 135.2, 133.7, 116.1 (C-Ar), 82.7 
(d, 2JP-C = 12.4 Hz, C-NH), 62.8 (d, 
2JP-C = 9.1 Hz, H2COP), 52.9 (MeCO2), 
49.6 (d, 1JP-C = 186.1 Hz, C-P), 
40.9 (NMe2), 16.9 (d, 3JP-C= 7.3 Hz, 
MeCOP)
4d 3320 (NH), 1698 
(C=O), 1242 (P=O, 
bonded), 1067 
(P-O-C)
1.02-1.18 (m, 9H, MeC.CO2, 2MeCOP), 
2.97 (s, 6H, NMe2), 3.25 (d, 2JP-H = 
19.5 Hz, 1H, HC-P), 4.16-4.23 (m, 6H, 
H2CCO2 & 2H2COP), 6.58, 7.67 (2d, 
3JH-H = 8.2 Hz, 4H, H-Ar), 8.54 (s, 1H, 
HC-triazole), 9.35 (br, 1H, HN); dP 
28.4
165.4 (C(5)-triazole), 164.1 (d, 2JP-C = 
8.8 Hz, C=O), 142.4 (C(3)-triazole), 
148.3, 134.8 132.9, 118.6 (C-Ar), 81.9 
(d, 2JP-C = 12.7 Hz, C-NH), 62.5 
(d, 2JP-C = 9.7 Hz, H2COP), 61.8 
(H2CCO2), 50.3 (d, 1JP-C = 196.2 Hz, 
C-P), 41.3 (NMe2), 16.3 (d, 3JP-C= 
7.8 Hz, MeCOP), 14.7 (MeC.CO2)
4e 3330-3318 (NH, 
NH2), 1249 (P=O, 
bonded), 1048 
(P-O-C)
1.20 (dt, 3JH-H = 7.2, 4JP-H  = 4.3 Hz, 6H, 
2MeCOP), 3.21 (d, 2JP-H = 20.8 Hz, 1H, 
HC-P), 4.23 (dq, 3JH-H = 7.2 Hz, 3JP-H = 
6.2 Hz, 4H, 2CH2OP), 7.24, 8.25 (2d, 
3JH-H = 9.4 Hz, 4H, H-Ar), 8.48 (s, 1H, 
HC-triazole), 9.23, 9.93 (2br, 3H, HN, 
H2N); dP 28.4
211.6 (d, 2JP-C = 11.8 Hz, C=S), 160.2 
(C(5)-triazole), 141.3 (C(3)-triazole), 
145.5, 135.7, 133.9, 132.2 (C-Ar), 76.5 
(d, 2JP-C = 11.7 Hz, C-NH), 61.3 (d, 
2JP-C = 9.6 Hz, H2COP), 59.3 (d, 1JP-C = 
168.6 Hz, C-P), 16.7 (d, 3JP-C = 6.8 Hz, 
MeCOP)
4f 3338 (NH), 2208 
(CN), 1235 (P=O, 
bonded), 1110 
(P-O-C)
1.19 (dt, 3JH-H = 6.9, 4JP-H  = 4.8 Hz, 6H, 
2MeCOP), 3.06 (d, 2JP-H = 26.3 Hz, 1H, 
HC-P), 4.26 (dq, 3JH-H = 6.9, 3JP-H = 
6.8 Hz, 4H, 2H2COP), 7.32, 8.16 (2d, 
3JH-H = 9.4 Hz, 4H, H-Ar), 8.63 (s, 1H, 
HC-triazole), 9.54 (br, 1H, HN); dP 
26.4
157.9 (C(5)-triazole), 140.8 (C(3)-tri-
azole), 142.6, 136.2, 133.4, 131.3 
(C-Ar), 116.8 (d, 2JP-C = 12.5 Hz, CN), 
77.8 (d, 2JP-C = 12.7 Hz, C-NH), 62.7 
(d, 2JP-C = 10.9 Hz, H2CO), 42.9 (d, 
1JP-C = 178.6 Hz, C-P), 17.3 (d, 3JP-C = 
7.3 Hz, MeCOP)
4g 3310 (NH), 1679 
(C=O), 1252 (P=O, 
bonded), 1123 
(P-O-C)
1.21 (dt, 3JH-H = 6.6, 4JP-H = 4.8 Hz, 6H, 
2MeCOP), 3.28 (d, 2JP-H = 19.8 Hz, 1H, 
HC-P), 3.71 (s, 3H, MeCO2), 4.22 (dq, 
3JH-H = 6.6, 3JP-H = 6.3 Hz, 4H, 2H2COP), 
7.26, 8.13 (2d, 3JH-H = 8.7 Hz, 4H, 
H-Ar), 8.57 (s, 1H, HC-triazole), 9.62 
(br, 1H, HN); dP 26.9
164.2 (d, 2JP-C = 8.7 Hz, C=O), 156.4 
(C(5)-triazole), 141.3 (C(3)-triazole), 
143.6, 134.5, 133.9, 133.2 (C-Ar), 82.3 
(d, 2JP-C = 12.7 Hz, C-NH), 62.3 (d, 
2JP-C = 13.6 Hz, H2COP), 52.4 
(MeCO2), 51.3 (d, 1JP-C = 159.8 Hz, 
C-P), 16.4 (d, 3JP-C = 7.8 Hz, MeCOP)
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4h 3327 (NH), 1708 
(C=O), 1227 (P=O, 
bonded), 1133 
(P-O-C)
1.22-1.30 (m, 9H, MeC.CO2 & 
2MeCOP), 3.26 (d, 2JP-H = 22.3 Hz, 1H, 
HC-P), 4.17-4.24 (m, 6H, H2CCO2 & 
2H2COP), 7.32, 8.24 (2d, 3JH-H = 8.2 Hz, 
4H, H-Ar), 8.65 (s, 1H, HC-triazole), 
9.46 (br, 1H, HN); dP 26.2
165.4 (d, 2JP-C = 11.3 Hz, C=O), 155.9 
(C(5)-triazole), 141.7 (C(3)-triazole), 
144.2, 135.1, 134.7, 133.8 (C-Ar), 82.7 
(d, 2JP-C = 13.5 Hz, C-NH), 62.8 (d, 
2JP-C = 10.7 Hz, H2COP), 61.5 
(H2CC-), 49.8 (d, 1JP-C = 188.6 Hz, 
C-P), 16.7 (d, 3JP-C = 6.2 Hz, MeCOP), 
14.2 (Me, ester)
6a 3415 (NH), 1262 
(P=O), 1115 
(P-O-C)
1.25 (dt, 3JH-H = 6.6, 4JP-H = 4.9 Hz, 6H, 
2MeCOP), 3.05 (s, 6H, Me2N), 4.12 
(dq, 3JH-H = 6.6, 3JP-H = 6.4 Hz, 4H, 
2H2COP), 6.62, 7.44 (2d, 3JH-H = 9.4 Hz, 
4H, H-Ar), 8.25 (s, 1H, HC-triazole), 
9.71 (s, 1H, HN); dP 29.4
155.8 (d, 2JP-C = 12.3 Hz, C-NH), 
146.3 (C(5)-triazole), 136.4 (d, 3JP-C = 
6.2 Hz, C(3)-triazole), 148.4, 130.5, 
124.3, 114.7 (C-Ar), 110.9 (d, 1JP-C = 
148.6 Hz, C-P), 60.7 (d, 2JP-C = 
10.9 Hz, H2COP), 40.5 (NMe2), 14.6 
(d, 3JP-C = 6.8 Hz, MeCOP)
6b 3433 (NH), 1264 
(P=O), 1085 
(P-O-C)
1.33 (dt, 3JH-H = 6.6, 4JP-H = 4.8 Hz, 6H, 
2MeCOP), 4.22 (dq, 3JH-H = 6.6, 3JP-H = 
6.8 Hz, 4H, 2H2COP), 6.92, 7.84 (2d, 
3JH-H = 8.9, 4H, H-Ar), 8.31 (s, 1H, 
HC-triazole), 9.76 (s, 1H, HN); dP 28.6
155.4 (d, 2JP-C = 12.9 Hz, C-NH), 
146.9 (C(5)-triazole), 135.4 (d, 3JP-C = 
5.9 Hz, C(3)-triazole), 136.4, 133.2, 
131.1, 129.3 (C-Ar), 109.8 (d, 1JP-C = 
128.2 Hz, C-P), 61.2 (d, 2JP-C = 
14.7 Hz, H2C), 14.1 (d, 3JP-C = 7.3 Hz
8a 1256 (P=O), 1075 
(P-O-C)
1.07, 1.12 (2d, 3JH-H = 6.5 Hz, 6H, 
HC-Me2), 1.29 (dt, 3JH-H = 7.1, 4JP-H = 
4.3 Hz, 6H, 2MeCOP), 3.33 (d.sept, 
3JH-H = 6.5, 3JP-H = 6.4 Hz, 1H, HC-Me2), 
3.48 (s, 6H, NMe2), 4.12 (dq, 3JH-H = 
7.1 Hz, 3JP-H = 7.5 Hz, 4H, 2H2COP), 
6.57, 7.61 (2d, 3JH-H = 9.4 Hz, 4H, H-Ar), 
8.33 (s, 1H, HC-triazole); dP 30.6
163.6 (d, 2JP-C = 18.6 Hz, C=N), 147.3 
(C(3)-triazole), 141.7 (d, 3JP-C = 
6.4 Hz, C(5)-triazole), 149.3, 137.6, 
134.6, 116.7 (C-Ar), 66.7 (d, 1JP-C = 
132.6 Hz, C-P), 62.2 (d, 2JP-C = 
12.4 Hz, H2COP), 39.4 (NMe2), 38.2 
(d, 2JP-C = 12.4 Hz, HC(CH3)2), 22.8 
(d, 3JP-C = 5.8 Hz, HCMe2), 15.7 (d, 
3JP-C = 6.8 Hz, MeCOP)
8b 1265 (P=O), 1065 
(P-O-C)
0.98, 1.11 (2d, 3JH-H = 6.9 Hz, 6H, 
Me2-CH), 1.26 (dt, 3JH-H = 7.8, 4JP-H = 
4.6 Hz, 6H, 2MeCOP), 3.38 (d. sept, 
3JH-H = 6.9, 3JP-H = 6.8 Hz, 1H, HC-Me2), 
4.23 (dq, 3JH-H = 7.8, 3JP-H = 6.7 Hz, 4H, 
2H2COP), 7.41, 8.02 (2d, 3JH-H = 8.6 Hz, 
4H, H-Ar), 8.36 (s, 1H, HC-triazole); 
dP 29.2
163.1 (d, 2JP-C = 17.8 Hz, C=N), 147.7 
(C(3)-triazole), 141.2 (d, 3JP-C = 6.8 Hz, 
C(5)-triazole), 140.5, 131.9, 130.2, 
128.6 (C-Ar), 67.2 (d, 1JP-C = 144.5 Hz, 
C-P), 61.8 (d, 2JP-C = 11.8 Hz, H2COP), 
38.8 (d, 2JP-C = 12.9 Hz, Me2-CH), 
22.3 (d, 3JP-C = 4.9 Hz, Me2-CH), 16.9 
(d, 3JP-C = 5.7 Hz, MeCOP)
a Solvent for NMR: CDCl3.
b Solvent for NMR: DMSO-d6.
sented as a list of activities in a table available as a supplementary document. The analysis 
of biological activity spectra prediction is an example of the in silico study of chemical 
compounds before experimental investigations. The biological activity spectrum for a sub-
stance is a list of biological activity types for which the probability to be revealed (Pa) and 
the probability to be inactive (Pi) are demonstrated. Pa and Pi values are independent and 
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their values vary from 0 to 1. PASS results showed that the antimicrobial and anticancer 
activities are the most common properties of the tested compounds.
Antimicrobial activity. – The antimicrobial activity of the synthesized phosphonates 
3a-h, 4a-h, 6a,b, 8a and b was individually tested against a panel of Gram-positive and 
Gram-negative bacterial pathogens Klebseilla peunomoniae 2011E, Pseudomonas aeruginosa 
6065 Y, Escherichia coli BW54, Escherichia coli BW55, Acinetobacter haemolyticus BW62, Steno-
Table III. Zone of growth inhibition (mm) of the new phosphor esters 3a-h, 4a-h, 6a, b, 8a and b
against some bacteria
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Cipro 10 8 11 12 9 8 11 15 11 12
Chlor 11 7 13 8 9 10 11 8 9 10
3a 7 5 8 4 6 5 7 5 ≤ 3b) 6
3b ≤ 3 ≤ 3 ≤ 3 ≤3 ≤ 3 ≤ 3 ≤ 3 ≤ 3 ≤ 3 ≤ 3
3c 7 5 5 6 7 6 5 ≤ 3 5 6
3d 7 6 4 7 8 4 ≤ 3 6 5 4
3e 6 5 8 6 ≤ 3 5 ≤ 3 6 5 4
3f ≤ 3 ≤ 3 ≤ 3 ≤3 ≤ 3 ≤ 3 ≤ 3 ≤ 3 ≤ 3 ≤ 3
3g 6 4 ≤ 3 6 ≤ 3 6 4 4 5 7
3h 6 7 4 5 5 6 4 ≤ 3 6 ≤ 3
4a 10 8 11 7 9 8 11 11 9 10
4b ≤ 3 ≤ 3 ≤ 3 ≤3 ≤ 3 ≤ 3 ≤ 3 ≤ 3 ≤ 3 ≤ 3
4c 11 10 7 8 8 7 10 6 8 7
4d 7 8 5 9 7 5 7 4 6 6
4e 8 9 8 7 5 10 6 6 8 7
4f ≤ 3 ≤ 3 ≤ 3 ≤3 ≤ 3 ≤ 3 ≤ 3 ≤ 3 ≤ 3 ≤ 3
4g 9 8 6 7 9 8 7 11 7 8
4h 6 7 5 6 ≤ 3 5 7 5 5 ≤ 3
6a 8 6 5 7 5 4 6 ≤ 3 5 6
6b 6 8 6 7 5 7 4 6 7 7
8a 7 8 7 8 9 ≤ 3 6 5 5 6
8b 4 6 5 6 4 4 ≤ 3 6 6 8
a Concentration of each used compound is 10 µmol L–1 (DMSO).
b Compounds with  < 3 mm growth inhibition zone were considered inactive.
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trophomonas maltophilia D457R, Staphylococcus epidermis 887E, Bacilllus cereus ATCC 11778, 
Staphylococcus aureus ATCC 29213 and Sacrina lutea. Ciprofloxacin (Cipro) and chloram-
phenicol (Chlor) were used as positive reference standards. Test compounds and drugs 
were used at a concentration of 10 µmol mL–1 (DMSO). Antimicrobial tests were carried out 
by the agar well diffusion method (21) using 100 L–1 of a suspension of the proper LB nutri-
ent broth containing 1 × 108 CFU mL–1 bacteria. The antimicrobial activity was evaluated 
by measuring the zone of inhibition against the tested organisms and compared with that 
of the standards. Antimicrobial activities were expressed as the inhibition diameter zones 
in millimeters (mm) and are presented in Table III. Each experiment was carried out in 
triplicate and the average zone of inhibition was calculated.
Minimal inhibitory (MIC) and minimal bactericidal concentration (MBC). – The bacterio-
static activity of the most active compounds 3a,e, 4a,c,e and g as well as the two reference 
drugs Cipro and Chlor was determined by the broth microdilution method on 96-well 
polystyrene flatbottom microtiter plates (Sarstedt, Germany), according to the Clinical 
Laboratory Standards Institute (CLSI) guidelines (22, 23). Antimicrobial activity was as-
sessed for each compound in the concentration range from 450 to 10 mmol L–1 (450, 200, 100, 
50, 25, 10 mmol L–1) in cation-adjusted Mueller Hinton (MH) medium (Fluka, Switzerland). 
Overnight incubated cultures (at 30 or 37 °C) as appropriate in MH, were standardized to 
0.5 McFarland units at 625 nm. Each compound-containing well and the positive control 
wells were inoculated with 2 × 108 CFU. Each plate included the positive control (bacteria 
without the antimicrobial) and the negative controls (medium only). The lowest concentra-
tion showing no growth was taken as the minimum inhibitory concentration (MIC). MIC 
was recorded as the lowest concentration of the compound that did not result in an absor-
bance at 595 nm that was higher than its respective control with compound after 24 h of 
incubation at 37 °C. Each assay was performed in triplicate. A strain is considered multi-
resistant when it is non-susceptible to at least 3 different classes of antimicrobial agents.
After 24 h of incubation, a spotting assay was performed in order to evaluate the 
minimum bacterial concentration (MBC). Plates were prepared using LB nutrient broth 
solid medium, dried in a laminar flux chamber and inoculated with 5 mL of the content of 
each microplate pit. Plates were incubated at 37 °C overnight for CFU counting. MBC was 
recorded as the lowest concentration that did not result in an eye-observable culture in 
solid medium after 24 h of incubation. Each assay was performed in triplicate.
Data of MIC / MBC are presented in Table IV.
Antitumor activity screening. – Antitumor potency of selected phosphonates 3a,c, 4a,c,e, 
g, 6a and 8a in addition to substrate 1 was tested at a dose of 10 mmol L–1 (DMSO) utilizing 
10 different human tumor cell lines. These lines represent breast [MCF7, MDA-MB-231/
ATCC, MDA-MB-435, BT-549), ovarian (IGROVI, OVCAR-3, SK-OV-3), prostate (PX-3, PU-
145), and liver (HEPG2) cells. Adriamycin (Adr) was used as a reference standard accord-
ing to the reported methods (24, 25). Using absorbance measurements at 515 nm for each 
compound, for control growth and for test growth, the percent growth inhibition was 
calculated at each of the tested compound concentration level. Susceptibility testing assays 
were undertaken three times. Growth inhibition of 50 % (GI50) was calculated. Further 
studies on experimental tumors in vivo for evaluating the possible antineoplastic potential 
of the most promising compounds are in progress.
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Table IV. MIC and MBC of phosphonates 3a,e, 4a,c,e and g, Cipro and Chlor against bacteria
Strain 3a  3e 4a 4c 4e 4g Cipro Chlor
K. peunomoniae
2011E
279 / 436 173 / 555 70 / 70 96 / 439 71 / 141 67 / 143 97 / 97 55 / 99
P. aeruginosa
6065Y
120 / 279 173 / 555 70 / 70 96 / 439 143 / 223 142 / 142 96 / 96 99 / 99
E. coli 
BW54 
120 / 279 66 / 222 65 / 140 66 / 141 22 / 44 142 / 448 96 / 96 49 / 198
E. coli
BW55 
130 / 279 142 / 142 70 / 140 70 / 70 143 / 286 142 / 287 377 / 377 396 / 396
A.haemolyticus 
BW62 
70 / 218 284 / 284 65 / 70 154 / 439 56 / 71 25 / 33 377 / 773 65 / 65
S. maltophilia 
D457R 
109 / 279 47 / 51 140 / 280 154 / 439 71 / 223 142 / 142 97 / 377 123 / 123
S. epidermis
887E
109 / 279 153 / 555 70 / 140 75 / 219 71 / 223 18 / 22 386 / 773 99 / 124
B. cereus
ATCC 11778 
140 / 436 178 / 222 70 / 140 88 / 219 143 / 223 287 / 448 48 / 96 111 / 111
S. aureus 
ATCC 29213 
140 / 436 178 / 222 54 / 121 88 / 141 71 / 223 287 / 448 96 / 96 198 / 619
Sacrina
lutea
87 / 218 142 / 142 54 / 121 121 / 219 71 / 223 146 / 287 97 / 377 198 / 619
MIC – minimum inhibitory concentration (µmol L–1), MBC – minimum bacterial concentration (µmol L–1), Cipro – 
ciprofloxacin, Chlor – chloramphenicol.
RESULTS AND DISCUSSION
Chemistry
Starting reaction sequences for the title compounds, b-amino- and fused thiadiazolo- 
and thiadiazinephosphonates, are outlined in Schemes 1-3. Upon treatment with Horner-
Wadsworth-Emmons (HWE) reagents (diethyl 2-amino-2-thioxoethyl-, cyanomethylphos-
phonate, methyl diethyl phosphonoacetate or triethyl phosphonoacetate), in DMF 
con taining LiH, 1,2,4-triazol-3-thiol substrates (1/2) yielded, after heating for appropriate 
time (≈6 h), the desired compounds 3a-h and 4a-h. b-Amino-phosphonates 3a-h (≈55 % 
yield) were obtained via nucleophilic addition reaction that led to hydrophosphonylation 
of the imine function in 1/2. In the IR spectra of 3a-h, NH and SH bands were observed at 
about 3434–3315 and 2480–2356 cm–1. Appearance of P=O (bonded) and P-O-C bands, re-
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spectively, at 1255–1228 and 1090–1024 cm–1 indicated the presence of a free SH group and 
confirmed preferred formation of an intramolecular hydrogen bond between the thiol-
proton and the phosphonate-oxygen atom. The configuration of 3 (dP ≈ 24.0 ppm) was as-
signed as E-configuration, based on the 1H NMR spectrum of, for example, 3a that revealed 
four types of methine protons with different chemical shifts. The multiplet at d 4.58 ppm 
was assigned to Hb-proton, while the P-CHa- proton resonated at 3.24 (dd, JHb-Ha = 15.7, 
2JP-H = 20.6 Hz) ppm. This large coupling constant (JH-H) of Hb with Ha as well as its coupling 
with phosphorus clearly indicates the anti-configuration of Ha to Hb-C*. In addition, the 
thiol-proton was displayed at 2.82 ppm (br) while the NH proton exhibited a doublet 
(JH-H = 6.8 Hz) at 10.33 ppm, confirming the presence of CHb and NH in a Z rearrangement. 
The enantiospecific isomer 3 was also verified by careful inspection of a model in terms of the 
Newman projection (26), which confirmed the staggered anticonfiguration of Hb and Ha. 
13C NMR spectrum of 3a revealed, among others, three doublets at dC 205.6 [d, 2JP-C = 10.4 Hz, 
C(S)], 63 (d, 2JP-C = 10.2 Hz, CHb-P), and d 58.5 (d, 1JP-C = 165.4 Hz, C-P), whereas Me2N moiety 
was displayed as a singlet at dC 39.5 ppm. The mass spectrum of 3a showed a peak corre-
sponding to the molecular ion at m/z (%): 458 (<7) [M+] and 456 (19) [M+-2] whereas the base 
peak was displayed at 215 (100) [M+ – 243 (2H + C(S)NH2 + NMe2 + PO(OEt)2)].
On the other hand, diethyl thiadiazole-5-methylenephosphonate (4a) was correctly 
identified as C17H25N6O3PS2, {m/z (%): 455 (19) [M+ – 1] and the base peak at 214 (100) [M+ – 242 
(H + C(S)NH2 + NMe2 + PO(OEt)2)]}. The 31P NMR spectrum of 4a, taken as an example, 
showed a positive signal at dP = 26.9 ppm (vs. H3PO4), which indicates the phosphonate 
structure. In the NMR spectra of 4a, the exocyclic methine moiety (CH-P) was found at dH 
3.22 (2JP-H = 18.8 Hz) and dC 58.7 ppm (d, 1JP-C = 172.4 Hz). These data excluded any possible 
cyclization reaction involving the methylphosphonate moiety (structure 5, Scheme 1), and 
3, 4 Ar R 3, 4 Ar R
a 4-Me2N-Ph C(S)NH2
e 4-Cl-Ph C(S)NH2
b 4-Me2N-Ph CN f 4-Cl-Ph CN
c 4-Me2N-Ph CO2Me
g 4-Cl-Ph CO2Me
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confirmed that the intramolecular cyclization proceeded via the other HC-Ar location. 
Furthermore, the 1H NMR spectrum of 4a showed other distinguished signals at d 1.22 (dt, 
3JH-H = 6.7, 4JP-H = 4.3 Hz, 6H) and 4.02 (dq, 3JH-H = 6.7 Hz, 3JP-H = 6.4 Hz, 4H), which were as-
signed to the two ethoxyl groups attached to phosphorus [(EtO)2P]. In addition, the N-di-
methyl protons appeared as a singlet at 2.91 (6H), while the NH and NH2 protons appeared 
as broad signals at 9.43 and 10.11 ppm. The 13C NMR spectrum of 4a showed the main signals 
at 207.6 (d, 2JP-C = 12.5 Hz, C=S), 159.2 [C(5)-triazole], 141.5 [C(3)-triazole], 148.5, 137.1, 132.7, 118.5 
(C-Ar), 77.5 (d, 2JP-C = 12.9 Hz, C-NH), 62.7 (d, 2JP-C = 8.7 Hz, H2COP), 58.7 (d, 1JP-C = 172.4 Hz, 
C-P), 39.1 (NMe2), and 15.7 ppm (d, 3JP-C= 6.9 Hz, H3CC-).
Obviously, while the nucleophilic addition of methylene-C in phosphonate reagents 
gave rise to products 3a-h, the slight homo-oxidation (air-oxidation) of 3 resulted in the 
formation of thiadiazoles 4 via intramolecular cyclization in tandem extrusion of a hydro-
gen molecule (27, 28). H-bond process was reported for the transformation of 3,5-di-tert-
butyl-2-hydroxyphenylamino derivatives to the corresponding benzoxazoles (14, 26). Fur-
ther, the air-oxidation process was previously discussed for the transformation of 
4{[(4-chlorophenyl)methylene]-amino}-3-mercapto-methyl-3,4-dihydro-1,2,4-triazin-
5(2H)-one to the respective fused pyrazoles (27). Thiadiazoles 4 were, however, exclu-
sively obtained in 75–80 % yield when the above reactions [1/2 and the same WHE re-
agents] proceeded in a methanol solution containing MeONa and a catalytic amount of 
2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) (29).
In contrast to the above results, reactions between 1/2 and diethyl [methyl(thioalkyl)]
phosphonates proceeded only when a catalytic amount of DDQ was present in the medi-
um (best yield, MeOH/MeONa/DDQ) and yielded, in each case, the same product, thiadi-
azine-2-phosphonates 6a,b (≈72 % yield). As displayed in Scheme 2, compounds 6a,b were 
formed via elimination of the alkylthiol motif from the initial intermediate 3i, followed by 
intramolecular cyclization. Structure 6a showed strong absorption bands at νmax 3415 (NH), 
1262 (P=O), and at 1115 (P-O-C) and disappearance of the band at 2420 cm–1 due to the SH 
group. The 1H NMR (d, ppm) did not show a signal either due to the SH proton supposed 
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protons were displayed at 1.25 (dt, JH-H = 6.6, 4JP-H= 4.9 Hz, 6H, 2MeCOP), and 4.12 (dq, 
JH-H = 6.6, 3JP-H= 6.4 Hz, 4H, 2H2COP) while the N-Me2 protons resonated as one singlet (6H) 
at 3.05. The 13C NMR spectrum of 6a showed, among others, sp3-C-(2) of the thiazine ring 
as a doublet (1JP-C= 148.6 Hz, C-P) at 110.9, whereas C(3) (thiazine) appeared as a doublet 
(3JP-C = 6.2 Hz) at 136.4. The 31P NMR shift of 6a was recorded at dP 29.4 ppm.
Finally, in a systematic study, 1,2,4-triazole-3-thiol-4-aminoarylidenes 1/2 were al-
lowed to react with diethyl(2-methylallyl)phosphonate in MeOH/MeONa/DDQ solution to 
give the fused thiadiazine-5-methylphosphonates 8a,b in ≈ 75 % yield. According to the 
mechanism outlined in Scheme 3, Michael addition by imine 1/2 onto the isomerized ylide 
form of the phosphonate reagent resulted in the formation of final products 8a,b via 
tandem loss of the H2 molecule from the initially formed intermediate 7. The 1H NMR 
spectrum (CDCl3) of 8a (dP ≈30 ppm) showed, among others, a doublet of septet (3JH-H = 6.5, 
3JP-H = 6.4 Hz, 1H) at d 3.33 ppm due to the exocyclic methine-proton (-CHMe2), two doublets 
(3JH-H = 6.5 Hz, 6H) at d 1.07, 1.12 ppm due to the exocyclic methyl groups, a singlet at 3.48 
ppm (6H) due to the Me2N moiety. The 13C NMR (CDCl3) spectrum of 8a displayed the 
-CHMe2 moiety at d 38.2 ppm (d, 2JP-C = 12.4 Hz) and at d 22.8 ppm (3JP-C = 5.8 Hz), while NMe2 
and C-P were, respectively, displayed at d 39.4 and 66.7 ppm (d, 1JP-C = 132.6 Hz).
Pharmacology
Antimicrobial evaluation. – Preliminary screening of new compounds 3a-h, 4a-h, 6a,b, 
8a and b was evaluated in vitro against a panel of standard and clinically isolated strains 
of the Gram-negative and Gram-positive bacteria using the disc diffusion method and the 
results are presented in Table III. All tested phosphonates, except the compounds 3b,f, 4b 
and f (compounds that have a nitrile moiety), exhibited some antimicrobial activity. Mea-
surement of the zone of growth inhibition for 10 mmol mL–1(DMSO) of each compound 
showed that the most active compounds were the fused thiadiazole-phosphonates 4a,c,e 
and g, which inhibited the growth of Gram-negative and Gram-positive bacteria. The most 
active compounds were selected for further screening. They all have in common the fused-
thiadiazole ring, which suggests that the presence of this motif may be enhancing the 
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MIC and MBC were then determined for the lead phosphonates 3a,e, 4a,c,e and g, as 
well as two reference drugs ciprofloxacin and chloramphenicol. The activity was assessed 
for each drug in the range of concentrations from 450 to 10 mmol L–1 (450, 200, 100, 50, 25, 10 
mmol L–1) in cation-adjusted Mueller Hinton medium (22) and the results are presented in 
Table IV.
The data displayed in Tables III and IV show that the two most active phosphonates 
were 4a and 4e with MIC of 54–140 and 22–143 mmol L–1, whereas their MBC values were 
70–439 and 44–268 mmol L–1 against all the pathogens tested. For comparison, MIC/MBC for 
ciprofloxacin were recorded at 48 to 386 (MIC, mmol L–1) and at 55 to 396 for MBC mmol L–1. 
On the other hand, MIC/MBC for chloramphenicol were recorded at 70 to 439 (MIC, mmol L–1) 
and at 65 to 619 for MBC mmol L–1.
Antitumor activity. – Inspired by the optimized results of the prediction analysis, anti-
tumor activity screening of 3a,c, 4a,c,e,g, 6a and 8a was tested applying carcinoma cell 
lines against adriamycin as a reference standard at a dose of 10 µmol L–1 (DMSO). Substrate 
1 was also tested at the same dose in a trial to reflect the effect of introducing phosphonate 
derivatives. The results are displayed in Table V and show an interesting activity for sev-
eral compounds. With the exception of substrate 1, all synthesized compounds reflected 
remarkable antitumor activity against breast (especially MDA-MB-231/ATCC and BT-549) 
and prostate carcinoma cell lines (PC-3 and DU-145), whereas a moderate to good effect 
was observed on ovarian and liver cancer cells. The order of activity for the tested com-
pounds is: 3a > 3c > 4a > 4e > 4c > 4g > 6a > 8a. Structure-activity relationship correlation 
for these compounds revealed that the presence of dialkylamino or 4-chloro as a substitu-
Table V. Growth inhibition (GI50 ) of Adr, 1, 3a,c, 4a,c, 6a and 8a in vitro human tumor cell lines
Panel/Cell line
GI50 (mmol L–1) for compounds
Adr 1 3a 3c 4a 4c 4e 4g 6a 8a
Breast cancer
MCF7 17.6 > 202a 19.2 27.5 31.5 41.3 49.8 38.5 67.5 59.7
MDA-MB-231/ATCC 26.4 > 202 23.9 14.4 27.2 30.7 41.3 11.3 60.9 12.1
MDA-MB-435 26.9 > 202 16.1 22.5 36.4 33.8 33.2 56.8 81.7 32.9
BT-549 16.6 > 202 22.9 31.7  37.9  41.3 25.9 24.2 40.5 40.2
Ovarian cancer
IGROVI 38.4 > 202 27.3 28.9 29.7 23.7 NAb 94.9 NA 56
OVCAR-3 26.9 > 202 25.3 31.9 31.8 27.7 30.6 81.7 71.6 NA
SK-OV-3 21.4 > 202 32.1 40.2 32 27.4 29.9 75.4 76.9 63.1
Prostat cancer
PX-3 15 > 202 10.5 19 24.5 15.1 8.48 NA 35.9 38.2
PU-145 28.3 > 202 11.8 22.7 20.8 NA 5.1 NA 39.2 19.9
Liver cancer
HEPG2 23.6 > 202 18.8 29.7 40.5 37.8 45.9 4.3 84.2 77
a Cell line growth inhibition with > 50% at a concentration of 10 mg L–1 was considered to be a noticeable activity. 
b NA: not active. Data are presented as the means Standard Deviation (± SD) of three independent experiments.
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ent on the aryl-moiety or as a substituent on the phosphonate moiety, is usually associated 
with enhancement of the antitumor property, as indicated in compounds 3a,c, 4a and in 
4e and 4g. In contrast to the antibiotic results, the data showed that the b-aminophospho-
nates 3a and c possess higher activity than their cyclic thiadiazole-counterparts 4a and c. 
In gene ral, compounds 3a, in particular 4e and 4g showed more significant antitumor ac-
tivity against tested carcinoma cell lines than the standard drug adriamycin. However, no 
straight correlation between the tumor activity and antibiotic efficacy of b-aminophospho-
nates and thiadiazoles or thiadiazines was found. This result is not surprising, since the 
targets of these two activities should be different. Further, the observed antibacterial activ-
ity, albeit weak, can be the result of non-specific cytotoxic effects (e.g., 6a and 8a), since 
bac teria can be killed in many ways.
CONCLUSIONS
We have developed a simple and convenient procedure for the preparation of a range 
of b-aminophosphonates 3a-h, fused-thiadiazole-5-methylphosphonates 4a-h and thiadi-
azinephosphonate derivatives from readily prepared 4-(4-(arylideneamino)-4H-1,2,4-tri-
azole-3-thiols 1/2. The antimicrobial evaluation showed that the most active compounds 
are the fused thiadiazole-phosphonates 4a,c,e and g, which inhibited the growth of Gram-
-negative and Gram-positive bacteria. On the other hand, the order of the antitumor prop-
erties for the tested selected compounds is: 3a > 3c (b-aminophosphonates) > 4a > 4e > 4c > 
4g (thiadiazolemethylphosphonates) > 6a > 8a (thiadiazine-phosphonates).
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